GlassScriptPhysician profile
Peter A Fischer
NPI 1235150756
$4,115.61
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,097 · 2020: $18.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $2,550.00 | 2019 | |
| Eli Lilly and Company | $733.09 | 2019 | |
| Lilly USA, LLC | $153.79 | 2019 | |
| Pfizer INC. | $134.38 | 2019-2020 | |
| Amgen INC. | $98.63 | 2019 | |
| Abbvie INC. | $82.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.23 | 2019 | |
| Celgene Corporation | $66.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $53.09 | 2019 | |
| Janssen Biotech, INC. | $42.20 | 2019 | |
| Genentech USA, INC. | $38.35 | 2019 | |
| Horizon Therapeutics Plc | $30.49 | 2019 | |
| Radius Health, INC. | $21.33 | 2019 | |
| Antares Pharma, INC. | $13.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $12.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.